GNL3

Across TCGA pan-cancer cohorts, GNL3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GNL3 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GNL3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNL3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and COAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where GNL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.388	0.752	<.001	57	view →
LUAD	DFS	Tertile	All	1.000	0.820	<.001	48	view →
PDAC	DFS	Tertile	III,IV	0.242	0.593	.001	44	view →
COAD	DFS	Median	All	1.000	0.887	.022	30	view →
HNSC	DFS	Tertile	All	0.333	0.892	.010	10	view →
LSCC	DFS	Tertile	II,III,IV	0.843	0.524	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GNL3–CCRCC (DFS)

Open the CCRCC breakdown →